rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ian Mortimer

President & CEO

Company insider

Files Form 4 as: President & CEO, Xenon Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
112
Buys
3
Sells
12
Bought
$1.2M
Sold
$44.0M
Companies
1
Companies where not an officer
0
First trade
17 Mar 2015
Last trade
30 Sep 2026
Last filed
1 Oct 2026

Companies traded

Where they are an officer
XENE Xenon PharmaceuticalsDirector, Officer · Biotechnology · last 30 Sep 20263 buys · 12 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
301Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Sep 2026filed 1 Oct 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Bought$1.1M30,000 at $37.38filing
13 Mar 2026filed 13 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$404K7,308 at $55.23filing
13 Mar 2026filed 13 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$404K7,308 at $55.23filing
12 Mar 2026filed 13 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M—12,500filing
12 Mar 2026filed 13 Mar 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—12,500 at $0.00filing
12 Mar 2026filed 13 Mar 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—12,500 at $0.00filing
12 Mar 2026filed 13 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M—12,500filing
10 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$677K11,269 at $60.11filing
10 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$677K11,269 at $60.11filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M$630K75,000 at $8.40filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$2.6M43,348 at $59.26filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$3.7M61,652 at $60.08filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M$614K65,000 at $9.44filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$4.0M65,000 at $62.06filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M—20,000filing
9 Mar 2026filed 11 Mar 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—75,000 at $0.00filing
9 Mar 2026filed 11 Mar 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—25,000 at $0.00filing
9 Mar 2026filed 11 Mar 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—105,000 at $0.00filing
9 Mar 2026filed 11 Mar 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—65,000 at $0.00filing
9 Mar 2026filed 11 Mar 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Sold$1.3M21,791 at $58.81filing

Sectors

Health Care15

Buys in green, sells in red, by the company’s sector.

Related people

Thomas Patrick KellyChief Financial Officer · Chief Financial Officer at Xenon Pharmaceuticals, filing Form 4 there in the last year
Dawn SvoronosDirector · Director at Xenon Pharmaceuticals, filing Form 4 there in the last year
Christopher John KenneyChief Medical Officer · Chief Medical Officer at Xenon Pharmaceuticals, filing Form 4 there in the last year
Steven GannonDirector · Director at Xenon Pharmaceuticals, filing Form 4 there in the last year
Gillian CannonDirector · Director at Xenon Pharmaceuticals, filing Form 4 there in the last year